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Introduction

Tumor lysis syndrome is a well-described phenomenon
characterized by elevated serum levels of calcium, uric acid,
potassium, phosphate, and lactate dehydrogenase due to lysis of
tumor cells and release of intracellular contents. Acute kidney
injury may occur as the result of precipitation of intrarenal
calcium phosphate salts related to the rapid destruction of
a large number of tumor cells. 1 Tumor lysis syndrome most
often occurs during induction chemotherapy for aggressive
leukemia or lymphoma, particularly those with large tumor
burden.1 While tumor lysis syndrome is more commonly seen
in patients receiving chemotherapy, it can occur spontaneously
and has been described in aggressive malignancies, such as
AML,2 Burkitt’s lymphoma in children1 and adults, 3 and in
solid malignancies, such as breast cancer.4 This case describes a
patient who presented with a neck mass and spontaneous tumor
lysis syndrome.

Case Presentation

A 76-year-old male with a past medical history of hypertension,
hyperlipidemia, and coronary artery disease presented with
epistaxis and a neck mass that was first noted four weeks prior to
presentation. In addition, the patient noticed gingival bleeding
when brushing his teeth, malaise, decreased appetite, and night
sweats, all of which developed during the previous week. His
exam was significant for an ulcer with scab on his left buccal
mucosa, a 6-cm left neck mass that was firm and non-tender,
and several areas of ecchymosis on his arms bilaterally. There
was no axillary or inguinal lymphadenopathy. The remainder of
the exam was unremarkable.
A neck ultrasound prior to admission showed multiple left
cervical cystic and solid masses consistent with necrotic lymph
nodes. The patient also had an enlarged right cervical lymph
node. He was admitted with a diagnosis of left neck mass
suspicious for malignancy and acute kidney injury.
On admission, laboratory data showed white blood cell count
of 5,300/mL, a platelet count of 3,000/mL, hemoglobin 12.5 g/
dL, and a mean corpuscular volume of 94 fL. The white cell
count differential included 23% neutrophils, 10% bands, 28%
lymphocytes, 13% atypical lymphocytes, 2% monocytes, 1%
metamyelocytes, 5% myelocytes, 2% promyelocytes, 16%
blasts, and 3.4/100 WBC nucleated red cells. Other significant
laboratory data included potassium of 4.5 mmol/L, blood urea
nitrogen (BUN) of 46 mg/dL, creatinine of 1.6 mg/dL, total
bilirubin of 2.1 mg/dL, direct bilirubin of 0.7 mg/dL, uric acid
of 17.4 mg/dL, and lactate dehydrogenase (LDH) of 4795 IU/L.
The patient’s elevated LDH, uric acid, and creatinine raised
suspicion of tumor lysis syndrome, so IV fluid hydration and

allopurinol were initiated. A bone marrow biopsy was performed
for diagnosis of suspected lymphoma. The patient’s creatinine,
LDH, and uric acid levels continued to rise, and treatment with
rasburicase was initiated given the concern for renal failure.
In less than 12 hours, the patient’s creatinine increased from
2.6 mg/dL to 3.5 mg/dL and potassium increased from 5.2
mmol/L to 6.1 mmol/L. The patient suffered cardiac arrest
before dialysis could be initiated. Although he was initially
resuscitated, care was withdrawn the same day per the patient’s
and family’s wishes.
The final bone marrow biopsy results, including flow cytometry
and FISH analysis, revealed solid monotonous sheets of large
atypical lympohoid cells with clear cytoplasmic vacuoles, which
accounted for the vast majority of nucleated bone marrow cells.
The cells demonstrated a monoclonal B-cell proliferation with
translocations at 8;22 involving the C-myc gene, consistent
with the diagnosis of Burkitt’s lymphoma. These results were
obtained several days after the patient had expired.

Discussion

Tumor lysis syndrome is a familiar entity to physicians caring
for patients receiving chemotherapy for treatment of leukemias
and lymphomas. This syndrome is most commonly encountered
upon initiation of chemotherapy in a patient for the first time,
but it can occur in any patient with extensive tumor burden,
including patients with solid malignancies. Patients may
exhibit hypercalcemia, hyperkalemia, hyperphosphatemia,
hyperuricemia and acute renal failure. Often prophylactic
intravenous fluid hydration and administration of allopurinol
or rasburicase are initiated prior to giving chemotherapy to
reduce the risk of developing renal failure and fatal arrhythmias
secondary to hyperkalemia. In addition, frequent monitoring of
serum potassium levels allows for treatment of hyperkalemia,
should it develop.
In the case presented above, tumor lysis syndrome was not
an anticipated event since chemotherapy was not being given
at the time of its development. Moreover, the patient had not
been diagnosed with a malignancy at the time of development
of the syndrome. Although it has been described before in the
literature, this uncommon presentation of spontaneous tumor
lysis syndrome could be easily missed. Knowing that spontaneous
tumor lysis syndrome can occur, it seems reasonable to obtain
serum lactate dehydrogenase and serum uric acid levels in
patients suspected of having a new diagnosis of a hematologic
malignancy even before the formal diagnosis is made. It is
important to initiate standard treatment of IV fluid hydration
and allopurinol or rasburicase as early as possible when tumor
lysis syndrome is suspected.
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